AstraZeneca PLC (AZN) on Tuesday said an interim analysis of its Phase III I CAN study showed that Ultomiris met the primary endpoint in adults with immunoglobulin A nephropathy.
The study demonstrated a statistically significant and clinically meaningful reduction in proteinuria at week 34.
The primary endpoints include change from baseline in proteinuria, measured by 24-hour urine protein creatinine ratio at week 34, and change in estimated glomerular filtration rate at week 106, to be assessed at the final analysis.
Ultomiris is already approved in the U.S., EU, Japan and other markets for the treatment of certain patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
It is also approved in multiple regions for certain adults with generalised myasthenia gravis and neuromyelitis optica spectrum disorder.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.